Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Andy Itsara, Victoria M. Rogness, Laura Samples, Constance M. Yuan, Hao-Wei Wang, Inhye E. Ahn, Mohammed Z.H. Farooqui, Xin Tian, Clare Sun, Emily Tomasulo, Susan Soto, Jeanine Superata, Larisa Bezkorovaynaya, Thomas E. Hughes, Pia K. Nierman, Adrian Wiestner

Blood blood.2025029971.

https://doi.org/10.1182/blood.2025029971

Published: 2025

Includes: Supplemental data

Journal Articles

Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia

Victoria Rogness, Bharath Dileep Kumar, Chingiz Underbayev, Pia Nierman, Clare Sun, Christine Gruessner, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 5653.

https://doi.org/10.1182/blood-2025-5653

Published: 2025

Journal Articles

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

Christine Gruessner, Victoria Rogness, Bharath Dileep Kumar, Rohan Herur, Laura Samples, Clare Sun, Lita Freeman, Pia Nierman, Chingiz Underbayev, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 7406.

https://doi.org/10.1182/blood-2025-7406

Published: 2025

Journal Articles

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

Layla M. Saleh, Maissa Mhibik, Heribert Playà-Albinyana, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2024) 144 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2024-198141

Published: 2024

Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 761.

https://doi.org/10.1182/blood-2024-201006

Published: 2024

Journal Articles

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Christine Gruessner, Alessandra Brofferio, Emily Tomasulo, Jeanine Superata, Shellin Jose, Susan Soto, Said Hafizullah Fayaz, Christopher Pleyer, Pia Nierman, Ovsanna Melikyan, Adrian Wiestner, Mark Haigney, Clare Sun

Blood (2024) 144 (Supplement 1): 6787.

https://doi.org/10.1182/blood-2024-205119

Published: 2024

Journal Articles

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Christopher Pleyer, Emily Tomasulo, Jeanine Superata, Rachel Adams, Xin Tian, Jayson Grey, Pia Nierman, Adrian Wiestner, Clare Sun

Blood (2024) 144 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2024-203506

Published: 2024

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2023-178819

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Layla M. Saleh, Maissa Mhibik, Jonathan Chen, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2023-190376

Published: 2023

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood (2023) 141 (13): 1584–1596.

https://doi.org/10.1182/blood.2022016934

Published: 2023

Includes: Supplemental data

Journal Articles

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Andy Itsara, Clare Sun, Inhye E. Ahn, Susan Soto, Douglas Rosing, Mark Haigney, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 4169–4170.

https://doi.org/10.1182/blood-2022-159716

Published: 2022

Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 2329–2332.

https://doi.org/10.1182/blood-2022-164772

Published: 2022

Journal Articles

Ibrutinib-Associated Sudden Death in Patients with CLL

Emily Bryer, Andy Itsara, Inhye E. Ahn, Beth Kozel, Cody Peer, William D. Figg, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 4133–4134.

https://doi.org/10.1182/blood-2022-160397

Published: 2022

Journal Articles

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9847–9848.

https://doi.org/10.1182/blood-2022-159525

Published: 2022

Journal Articles

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Anfal Alsadhan, Jonathan Chen, Clare Sun, Chingiz Underbayev, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 6004–6005.

https://doi.org/10.1182/blood-2022-163370

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 9896–9897.

https://doi.org/10.1182/blood-2022-162365

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Ibrutinib-Associated Sudden Death in Patients with CLL

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only